TREATMENT ADHERENCE OF COVID-19 PATIENTS GETTING MEDICATION AT HOME

Ahmet Onder Porsuk, Cigdem Cerit

Abstract


Introduction: Turkey has adopted outpatient treatment of COVID-19 since the beginning of the pandemic. In the outpatient treatment of COVID-19 in Turkey, only hydroxychloroquine was initially used, favipiravir was added to the treatment, and finally, hydroxychloroquine was removed from the treatment and only favipiravir was used. Our study aims to examine the adherence to the recommended treatment of people diagnosed with COVID-19 who have received outpatient treatment without hospitalization and their attitudes and declared behaviors towards using the medications they were given free of charge.

Methods: This follow-up study was conducted between February 15, 2021, and May 15, 2021, by telephone survey method in the Lüleburgaz District of Kırklareli City. The study participants were 4368 people who were diagnosed with COVID-19 with a positive PCR test in Lüleburgaz District between February 15 and May 15, 2021, and were given hydroxychloroquine and/or favipiravir drugs for home use after being deemed suitable for outpatient treatment according to the guidelines of the Republic of Turkey Ministry of Health.

Results: 88.1% (n=3849) of the survey respondents reported using the given medications regularly, while 11.9% (n=519) did not use them regularly. The most important socio demographic factor affecting the regular use was age, and the patient-centered factor was the sense of trust.

Conclusion: In the fight against COVID-19, measures to increase the sense of trust of patients who are expected to adhere to the treatments should be considered a priority.


Keywords


COVID-19, Favipiravir, Hydroxychlorochin, Medication Adherence, Outpatient Therapy

Full Text:

PDF

References


Aslan R. Endemic diseases in history and today and COVID-19. AyrıntıDergisi.2020; 8(65): 35-41.

Atalay S, Ersan G. COVID-19 tedavisi. Tepecik Eğit. ve Araşt. Hast. Dergisi. 2020;30(Ek sayı):126-34. doi:10.5222/terh.2020.48030.

İnkaya AÇ, Taş Z, Akova M. Current treatment of COVID-19. Editors: Yalçın Ş, Özet A.Cancer and the COVID-19 Pandemic. 1st Edition. TürkiyeKlinikleri.Ankara: 2020, p.27-37.

EKMUD (Turkish Infectious Diseases and Clinical Microbiology Specialization Association). T. R. Ministry of Health COVID-19 Guidelines Archive. Available online:

https://www.ekmud.org.tr/haber/453-t-c-saglik-bakanligi-covid-19-rehberleri-arsivi(accessed on 15.08.2021)

Yılmaz S. During the Covid-19 pandemic overview of the dynamic changes in the Guidelines published by the Ministry of Health. Journal of ADEM. 2020;1(2): 20-30.

Yeşil E, Cengiz N, Acar Ş. The agents used in the treatment in Turkey COVID-19. Sakarya Med J. 2021;11(2): 452-7. doi: 10.31832/smj.798697 .

Koca Z. Good Governance practices in health during Covid-19: The case of Turkey Kafkas University Journal of the Faculty of Economics and Administrative Sciences. 2021; 12(23): 415-51. doi:10.36543/kauiibfd.2021.019 .

Sabate E. WHO Adherence Meeting Report. Geneva, World Health Organization. 2001.

Madani SJ, Larijani B, Nedjat S, Bagheri A. Family medicine ethical issues regarding physician-patient interactions from patients' perspectives: A qualitative study. Caspian J Intern Med.2021; 12(2):184-93. doi:10.22088/cjim.12.2.184 .

WHO. Adherence to long-term therapies: evidence for action. Geneva, World Health Organization.,2003.

Anghel LA, Farcas AM, Oprean RN. An overview of the common methods used to measure treatment adherence. Med Pharm Rep. 2019; 92(2):117-22. doi:10.15386/mpr-1201 .

Risch HA. Early outpatient treatment of symptomatic, high-risk COVID-19 patients that should be ramped up immediately as key to the pandemic crisis. Am J Epidemiol. 2020; 189(11):1218-26. doi: 10.1093/aje/kwaa093.

Mc Cullough PA, Kelly RJ, Ruocco G, Lerma E, Tumlin J, Wheelan RK et al. Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection. Am J Med. 2021;134(1):16-22. doi: 10.1016/j.amjmed.2020.07.003.

Stricker RB, Fesler MC. Hydroxychloroquine pre-exposure prophylaxis for COVID-19 in healthcare workers from India: a meta-analysis. J Infect Public Health. 2021;14(9):1161-3. doi: 10.1016/j.jiph.2021.08.001.

Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: A review from the patient's perspective. Ther Clin Risk Manag. 2008;4(1):269-86. doi:10.2147/tcrm.s1458

Harbalıoğlu H, Genc O, Yıldırım A. 3 predictors of hospitalization in patients with coronavirus (Covid-19): old age, lactate dehydrogenase, and neutrophil/lymphocyte ratio. Pam Tıp Derg. 2021; 14(1): 57-62. doi:10.31362/patd.751093 .

Deniz S, Çimen M. Hekimlere Güven Düzeyinin Belirlenmesine Yönelik Bir Araştırma. CBU-SBED.2020; 8(1): 10-66. doi: 10.34087/cbusbed.656592 .

Kayhan Omeroglu S, Temel F, Altun D, Öztop MB. Effects of hydroxychloroquine and favipiravir on clinical course in outpatients with COVID-19. Turkish journal of medical sciences. 2021;51(6):2827-34.doi: 10.3906/sag-2101-146.

Siordia JA Jr, Bernaba M, Yoshino K, Ulhaque A, Kumar S, Bernaba M et al. Systematic and statistical review of Coronavirus Disease 19 treatment trials. SN Comp Clin Med. 2020;2(8):1120-31. doi: 10.1007/s42399-020-00399-6.

Giammaria D, Pajewski A. Can early treatment of patients with risk factors contribute to managing the COVID-19 pandemic?. J Glob Health. 2020;10(1):010377. doi:10.7189/jogh.10.010377.

Tuccori M, Convertino I, Ferraro S, Cappello E, Valdiserra G, Focosi D. et al. The Impact of the COVID-19 “Infodemic” on drug-utilization behaviors: implications for pharmacovigilance. Drug Saf. 2020; 43: 699 – 709. doi: 10.1007/s40264-020-00965-w .

Khan N, Gattani P, Inamdar IA, Domple V, Nina MB. Coverage evaluation and compliance of mass drug administration campaign in Nanded District of Maharashtra. Natl J Community Med. 2017; 8(11): 684-7.

Goudarzi H, Barati M, Bashirian S, Moeini B. Determinants of medication adherence among hypertensive patients using Pender's health promotion model. J Educ Health Promot. 2020; 9:89. doi:10.4103/jehp.jehp_687_19 .

Koulayev S, Simeonova E, Skipper N. Can physicians affect patient adherence with medication? Health Econ. 2017;26(6): 779-94. doi: 10.1002/hec.3357.

Dabbous HM, El-Sayed MH, El Assal G, Elghazaly H, Ebeid FFS, Sherief AF, et al. Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomized controlled trial. Scientific reports. 2021; 11 (1): 7282. doi: 10.1038/s41598-021-85227-0 .

Bosaeed M, Mahmoud E, Hussein M, Alharbi A, Alsaedy A, AlothmanA, et al. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomized controlled trial. Trials. 2020; 21 (1): 904. doi: 10.1186/s13063-020-04825-x .

Mermit Çilingir B, Sunnetcioglu A, Yıldız H, Erçek B, Baykal N. What is the case of more accessible treatment options in COVID 19: comparison of Hydroxychloroquine and Favipiravir based on laboratory values? East J Med. 2021; 26(3): 426-32. doi: 10.5505/ejm.2021.46548




DOI: http://dx.doi.org/10.5937/sanamed17-36529

Refbacks

  • There are currently no refbacks.


Copyright (c) 2022 Ahmet Önder Porsuk, Çiğdem Cerit

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.